Population Health Sciences

You are here

Home > Publications > Publications

Publications

Found 295 results
Author [ Title(Desc)] Type Year
Filters: First Letter Of Last Name is B  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
O
Hupert N, Biala K, Holland T, Baehr A, Hasan A, Harvey M.  2015.  Optimizing Health Care Coalitions: Conceptual Frameworks and a Research Agenda.. Disaster Med Public Health Prep. 9(6):717-23.
P
Cea ME, M Reid C, Inturrisi C, Witkin LR, Prigerson HG, Bao Y.  2016.  Pain Assessment, Management, and Control Among Patients 65 Years or Older Receiving Hospice Care in the U.S.. J Pain Symptom Manage. 52(5):663-672.
Bao Y, Fan G, Zou D, Wang T, Xue D.  2017.  Patient experience with outpatient encounters at public hospitals in Shanghai: Examining different aspects of physician services and implications of overcrowding.. PLoS One. 12(2):e0171684.
Mullangi S, Bhandari R, Thanaporn P, Christensen M, Kronick S, Nallamothu BK.  2020.  Perceptions of resuscitation care among in-hospital cardiac arrest responders: a qualitative analysis.. BMC Health Serv Res. 20(1):145.
Martin P, Bartlett NL, Blum KA, Park S, Maddocks K, Ruan J, Ridling LA, Dittus C, Chen Z, Huang X et al..  2019.  A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.. Blood. 133(11):1201-1204.
Martin P, Bartlett NL, Blum KA, Park S, Maddocks K, Ruan J, Ridling LA, Dittus C, Chen Z, Huang X et al..  2019.  A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.. Blood. 133(11):1201-1204.
Tagawa ST, Vallabhajosula S, Christos PJ, Jhanwar YS, Batra JS, Lam L, Osborne J, Beltran H, Molina AM, Goldsmith SJ et al..  2019.  Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ( Lu-J591) for metastatic castration-resistant prostate cancer.. Cancer. 125(15):2561-2569.
Tagawa ST, Vallabhajosula S, Christos PJ, Jhanwar YS, Batra JS, Lam L, Osborne J, Beltran H, Molina AM, Goldsmith SJ et al..  2019.  Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ( Lu-J591) for metastatic castration-resistant prostate cancer.. Cancer. 125(15):2561-2569.
Tagawa ST, Vallabhajosula S, Christos PJ, Jhanwar YS, Batra JS, Lam L, Osborne J, Beltran H, Molina AM, Goldsmith SJ et al..  2019.  Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ( Lu-J591) for metastatic castration-resistant prostate cancer.. Cancer. 125(15):2561-2569.
Batra JS, Niaz MJunaid, Whang YE, Sheikh A, Thomas C, Christos P, Vallabhajosula S, Jhanwar YS, Molina AM, Nanus DM et al..  2020.  Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (Lu-J591) for metastatic castration-resistant prostate cancer.. Urol Oncol.
Batra JS, Niaz MJunaid, Whang YE, Sheikh A, Thomas C, Christos P, Vallabhajosula S, Jhanwar YS, Molina AM, Nanus DM et al..  2020.  Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (Lu-J591) for metastatic castration-resistant prostate cancer.. Urol Oncol.
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..  2019.  A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res. 25(1):43-51.
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..  2019.  A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res. 25(1):43-51.
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..  2019.  A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res. 25(1):43-51.
Jung H-Y, Unruh MAaron, Vest JR, Casalino LP, Kern LM, Grinspan ZM, Bao Y, Kaushal R.  2017.  Physician Participation in Meaningful Use and Quality of Care for Medicare Fee-for-Service Enrollees.. J Am Geriatr Soc. 65(3):608-613.
Gupta A, Kesavabhotla K, Baradaran H, Kamel H, Pandya A, Giambrone AE, Wright D, Pain KJ, Mtui EE, Suri JS et al..  2015.  Plaque echolucency and stroke risk in asymptomatic carotid stenosis: a systematic review and meta-analysis.. Stroke. 46(1):91-7.
Press MJ, Gerber LM, Peng TR, Pesko MF, Feldman PH, Ouchida K, Sridharan S, Bao Y, Barron Y, Casalino LP.  2015.  Post-Discharge Communication Between Home Health Nurses and Physicians: Measurement, Quality, and Outcomes.. J Am Geriatr Soc. 63(7):1299-305.
Press MJ, Gerber LM, Peng TR, Pesko MF, Feldman PH, Ouchida K, Sridharan S, Bao Y, Barron Y, Casalino LP.  2015.  Post-Discharge Communication Between Home Health Nurses and Physicians: Measurement, Quality, and Outcomes.. J Am Geriatr Soc. 63(7):1299-305.
Bao Y, Eggman AA, Richardson JE, Sheeran TF, Bruce ML.  2015.  Practices of Depression Care in Home Health Care: Home Health Clinician Perspectives.. Psychiatr Serv. 66(12):1365-8.
Bao Y, Eggman AA, Richardson JE, Sheeran TF, Bruce ML.  2015.  Practices of Depression Care in Home Health Care: Home Health Clinician Perspectives.. Psychiatr Serv. 66(12):1365-8.
Adekkanattu P, Rasmussen LV, Pacheco JA, Kabariti J, Stone DJ, Yu Y, Jiang G, Luo Y, Brandt PS, Xu Z et al..  2023.  Prediction of left ventricular ejection fraction changes in heart failure patients using machine learning and electronic health records: a multi-site study.. Sci Rep. 13(1):294.
Adekkanattu P, Rasmussen LV, Pacheco JA, Kabariti J, Stone DJ, Yu Y, Jiang G, Luo Y, Brandt PS, Xu Z et al..  2023.  Prediction of left ventricular ejection fraction changes in heart failure patients using machine learning and electronic health records: a multi-site study.. Sci Rep. 13(1):294.
Meinhofer A, Williams ARobin, Johnson P, Schackman BR, Bao Y.  2019.  Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events? J Subst Abuse Treat. 105:37-43.
Wen H, Hockenberry JM, Jeng PJ, Bao Y.  2019.  Prescription Drug Monitoring Program Mandates: Impact On Opioid Prescribing And Related Hospital Use.. Health Aff (Millwood). 38(9):1550-1556.
Bao Y, Pan Y, Taylor A, Radakrishnan S, Luo F, Pincus HAlan, Schackman BR.  2016.  Prescription Drug Monitoring Programs Are Associated With Sustained Reductions In Opioid Prescribing By Physicians.. Health Aff (Millwood). 35(6):1045-51.